GSK Puerto Rico Plant Under Investigation By FDA; Received Warning In 2002
GlaxoSmithKline does not anticipate any immediate supply disruptions from an FDA investigation of its Cidra, Puerto Rico production facility
You may also be interested in...
Schering-Plough has been named in a False Claims Act suit alleging the company (and two dozen other manufacturers) knowingly sold adulterated products to the federal government
GlaxoSmithKline expects to resolve GMP issues related to production of Paxil oral suspension at its Certenejas Cidra, Puerto Rico facility by the end of the month, the company said
GlaxoSmithKline's manufacturing streamlining has helped the company avoid trouble during the recent round of FDA good manufacturing practices enforcement, CEO J.P. Garnier told investors Oct. 23